Verastem
Verastem Oncology is seeking a Senior Medical Director to provide medical and scientific leadership for late-phase solid tumor clinical development, focusing on the VS-7375 KRAS G12D ON/OFF inhibitor program. The role involves leading the medical aspects of Phase 3 pivotal trials, overseeing medical monitoring, and contributing to regulatory filings and marketing authorization activities. This position requires extensive experience in oncology clinical development and cross-functional collaboration to advance cancer care.
Headquarters
Needham Heights, Massachusetts, United States
Company Size
51-200 employees
Founded
2010
Verastem Oncology is a biopharmaceutical company focused on developing and delivering novel therapies for RAS/MAPK pathway-driven cancers. The company has advanced the first FDA-approved treatment for KRAS-mutant recurrent low-grade serous ovarian cancer and maintains a pipeline of small molecule inhibitors targeting KRAS G12D, RAF/MEK, and FAK pathways. Verastem leverages strategic collaborations and ongoing clinical trials to address significant unmet needs across multiple solid tumor types.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Verastem.
Vice President, Global Clinical Lead - Solid Tumor
BioLife Plasma Services
Global Development Medical Director, Hematology Oncology
AstraZeneca
Global Development Associate Medical Director Barcelona Spain
AstraZeneca
Senior Medical Director, Oncology Clinical Development
Zailab
Senior Medical Director, Oncology Clinical Development (Office Based - Cambridge, MA)
Zailab
Global Development Medical Director, Hematology Oncology
AstraZeneca